CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
SPR001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03257462
NCT03257462Phase 2Completed
CompareCT.gov

A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)

Spruce Biosciences·interventional·Posted Aug 22, 2017·Updated Oct 22, 2025

In Brief

A Phase 2 clinical trial evaluating SPR001 for Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia. Completed, enrolled 24 participants across 9 sites.

Detailed Summary

This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 22, 2017
Enrollment StartJul 12, 2017
Primary CompletionMar 2, 2019
Study CompletionMar 29, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.9 years ago

Interventions

SPR001drug

SPR001 Capsules